Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2003

View Archived Issues

New tricyclic macrolide antibiotics identified at Abbott

Merck describes new selective androgen receptor modulators for osteoporosis therapy

Another series of chemokine CCR2 modulators newly identified at Merck

Novel anti-herpes virus agents prepared and tested by GSK team

Genelabs patent covers new NS5B inhibitors for HCV infection

Pivotal stage of AI-700 phase III program commences

Kinexium to manage development of new departments at Generex

Phase I trial tests FG-3019 in IPF patients

Second approvable letter for Symlin

Naropin recommended for E.U. approval for new indication

Second phase II trial for Corus-1030

CTCE-9908 enters phase I testing

Enrollment goal reached for phase III Xibrom trial

Orphan drug designation for Photopoint MV-2101

BAMF Technology to be transitioned to Eclipse Diagnostics

Oxford BioMedica oncology pipeline update

deCODE achieves milestones in Roche DNA-based diagnostics alliance

MLN-2222 enters phase I

Clinical effects of PKC-412 in acute myeloid leukemia

Antitumor activity of thalidomide analogues in hematological malignancies

Cardioprotection against ischemia/reperfusion injury via PPARalpha activation shown in mice

Septic diaphragm dysfunction attenuated with geranylgernaylacetone induction of HSD70 in rats

NDA for lower dose Yasmin accepted for filing

XTL Biopharmaceuticals reviews recent developments

GW-4064, a FXR agonist, provides hepatoprotection in rat models of cholestasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...